- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07942090
Role of 68Ga-FAPI PET/CT in Patients in Whom 18F-FDG PET/CT Has Been Found to be Questionable or Inconclusive Due to Oncological Pathology (FAPI-MN-2020)
To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Study Overview
Status
Intervention / Treatment
Detailed Description
Studied population Approximately 200 patients will be enrolled with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Patients enrolled must satisfy all the inclusion criteria and must sign an informed consent. The informed consent will be signed by the patient in the nuclear medicine department before the performance of any experimental procedure.
Primary aim
Secondary aim
To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
To evaluate accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Primary endpoint accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Secondary enpoint accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Italy
-
Bologna, Italy, Italy, 40138
- IRCCS Azienda Ospedaliero Universitaria di Bologna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Inclusion criteria • Age ≥18 years old
- Both sexes
- Patients with oncological disease suspicion/ new diagnosis or with a previously treated tumour (with previous treatments performed at least 3 months before enrollment) and with an inconclusive or equivocal [18F]F-FDG PET/CT, especially cases of:
-
Suspect primary or secondary (lymph-nodes or distant metastases) lesions with absent/faint FDG uptake or low TBR;
-
And/or suspect primary or secondary (lymph-nodes or distant metastases) lesions in a site of phisiological FDG uptake (such as brain or liver) or in sites in which FDG has a low sensitivity (i.e. peritoneal carcinomatosis, esophageal-gastro-intestinal tract);
-
And/or low glucose metabolism tumour hystotypes (i.e. renal clear cell carcinoma, mucinous mammary tumours, well differentiated HCC);
-
And/or differential diagnosis between tumour and inflammation (i.e. determining lymph-nodes benign or malignant nature in head/neck cancers, differential diagnosis between inflammation or malignant tissue in sarcomas).
- Signed informed consent
Exclusion Criteria: Exclusion Criteria • Pregnancy. In order to rule out pregnancy a β-hCG blood test will be performed in women of childbearing age.
- Breastfeeding
- Patients in emergency situations or unfit to plead.
- History of allergic reactions or hypersensitivity to the active substance, to any of the excipients, or to any of the components of the radiolabeled radiopharmaceutical
- Contraindication to PET / CT examination for patients unable to perform PET due to weight, claustrophobia or the inability to remain still for the duration of the examination
- Participation in a clinical trial in which an investigational drug was administered within 30 days or 5 half-lives before the study drug
- Patients with impaired renal function;
- Patients with impaired liver function;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
diagnostic performance
Time Frame: 9 years
|
sensitivity, specificity, AUC, detection rate, accuracy, positive and negative predictive value compared to the reference standard. |
9 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jager D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2.
- Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z. Epub 2020 Mar 28.
- Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Rohrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jager D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Respiratory Tract Diseases
- Genital Diseases, Female
- Lung Diseases
- Endocrine Gland Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Skin Diseases
- Breast Diseases
- Skin and Connective Tissue Diseases
- Lung Neoplasms
- Ovarian Neoplasms
- Breast Neoplasms
- Head and Neck Neoplasms
- 68Ga-FAPI
Other Study ID Numbers
- FAPI-MN-2020
- 2020-005549-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.